Sareum Ltd is a UK-based biotechnology company founded in 2003, listed on the AIM market of the London Stock Exchange under the ticker SAR. The company focuses on developing next-generation kinase inhibitors for autoimmune diseases and cancer. Its lead candidate, SDC-1801, is a potential treatment for autoimmune diseases and has entered Phase 1a/b clinical development, with an initial focus on psoriasis. Sareum also has an economic interest in SRA737, a clinical-stage Chk1 inhibitor, which has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Moreover, Sareum is developing SDC-1802, a TYK2/JAK1 inhibitor with potential application for cancer immunotherapy. The last investment in Sareum Ltd was a £2.00M post-IPO debt investment on 03 August 2023 by Riverfort Global Opportunities PLC. The company operates in the biotechnology, health and wellness, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | £2.00M | 1 |
|
03 Aug 2023 |
| Post-IPO Equity | £900.00K | - | 03 Jun 2021 |
No recent news or press coverage available for Sareum Ltd.
We care about your data, and we'd love to use cookies make your experience better.
